These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. PET after chemotherapy identifies Hodgkin's lymphoma patients who can avoid radiotherapy. Mayor S BMJ; 2015 Apr; 350():h2190. PubMed ID: 25908591 [No Abstract] [Full Text] [Related]
27. First reported case of disease: peliosis hepatis as cardinal symptom of Hodgkin's lymphoma. Kleger A; Bommer M; Kunze M; Klaus J; Leithaeuser F; Wegener M; Adler G; Dikopoulos N Oncologist; 2009 Nov; 14(11):1088-94. PubMed ID: 19889716 [TBL] [Abstract][Full Text] [Related]
28. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ; Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730 [TBL] [Abstract][Full Text] [Related]
33. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V; J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249 [TBL] [Abstract][Full Text] [Related]
34. PET-Directed Therapy for Hodgkin's Lymphoma. Radford J; Illidge T; Barrington S N Engl J Med; 2015 Jul; 373(4):392. PubMed ID: 26200987 [No Abstract] [Full Text] [Related]
35. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma. Delbeke D; Stroobants S; de Kerviler E; Gisselbrecht C; Meignan M; Conti PS Oncologist; 2009; 14 Suppl 2():30-40. PubMed ID: 19819922 [TBL] [Abstract][Full Text] [Related]
36. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. Agostinelli C; Gallamini A; Stracqualursi L; Agati P; Tripodo C; Fuligni F; Sista MT; Fanti S; Biggi A; Vitolo U; Rigacci L; Merli F; Patti C; Romano A; Levis A; Trentin L; Stelitano C; Borra A; Piccaluga PP; Hamilton-Dutoit S; Kamper P; Zaucha JM; Małkowski B; Kulikowski W; Tajer J; Subocz E; Rybka J; Steidl C; Broccoli A; Argnani L; Gascoyne RD; d'Amore F; Zinzani PL; Pileri SA Lancet Haematol; 2016 Oct; 3(10):e467-e479. PubMed ID: 27692305 [TBL] [Abstract][Full Text] [Related]
38. Spontaneous regression of Hodgkin's disease: two case reports and a review of the literature. Mangel J; Barth D; Berinstein NL; Imrie KR Hematology; 2003 Jun; 8(3):191-6. PubMed ID: 12745644 [TBL] [Abstract][Full Text] [Related]
39. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577 [TBL] [Abstract][Full Text] [Related]
40. Progressive pericardial effusion during chemotherapy for advanced Hodgkin lymphoma. Casey DJ; Kim AY; Olszewski AJ Am J Hematol; 2012 May; 87(5):521-4. PubMed ID: 22120982 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]